Literature DB >> 20638733

Measurement of anti-beta amyloid antibodies in human blood.

Paul Szabo1, Diana M Mujalli, Matthew L Rotondi, Rajal Sharma, Alfred Weber, Hans-Peter Schwarz, Marc E Weksler, Norman Relkin.   

Abstract

The human IgG repertoire contains endogenous antibodies against beta amyloid (Aβ) that may be relevant to the pathogenesis and treatment of Alzheimer's disease. There have been widely disparate estimates of the levels of these antibodies in human plasma. We identify factors that have contributed to these disparities and describe improved methods for measuring anti-Aβ antibodies in blood. These methods include isolating immunoglobulin by thiophilic chromatography and using chaotropic salts to dislodge weakly bound antibodies without significantly reducing the binding of specific anti-Aβ antibodies. Using these methods, we show that human blood contains polyvalent IgG antibodies that bind to Aβ with relatively low avidity and specificity, as well as IgG antibodies that bind to linear and conformational epitopes on amyloid monomers and aggregates with moderate to high avidity.
Copyright © 2010 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20638733     DOI: 10.1016/j.jneuroim.2010.06.010

Source DB:  PubMed          Journal:  J Neuroimmunol        ISSN: 0165-5728            Impact factor:   3.478


  22 in total

1.  Overview of immunotherapy in Alzheimer's disease (AD) and mechanisms of IVIG neuroprotection in preclinical models of AD.

Authors:  Scott E Counts; Debomoy K Lahiri
Journal:  Curr Alzheimer Res       Date:  2014       Impact factor: 3.498

2.  A human monoclonal IgG that binds aβ assemblies and diverse amyloids exhibits anti-amyloid activities in vitro and in vivo.

Authors:  Yona Levites; Brian O'Nuallain; Rama Devudu Puligedda; Tomas Ondrejcak; Sharad P Adekar; Cindy Chen; Pedro E Cruz; Awilda M Rosario; Sallie Macy; Alexandra J Mably; Dominic M Walsh; Ruben Vidal; Alan Solomon; Daniel Brown; Michael J Rowan; Todd E Golde; Scott K Dessain
Journal:  J Neurosci       Date:  2015-04-22       Impact factor: 6.167

3.  Intravenous immunoglobulin for Alzheimer's disease.

Authors:  N Relkin
Journal:  Clin Exp Immunol       Date:  2014-12       Impact factor: 4.330

Review 4.  Clinical trials of intravenous immunoglobulin for Alzheimer's disease.

Authors:  Norman Relkin
Journal:  J Clin Immunol       Date:  2014-04-24       Impact factor: 8.317

5.  A lipoprotein receptor cluster IV mutant preferentially binds amyloid-β and regulates its clearance from the mouse brain.

Authors:  Abhay P Sagare; Robert D Bell; Alaka Srivastava; Jesse D Sengillo; Itender Singh; Yoichiro Nishida; Nienwen Chow; Berislav V Zlokovic
Journal:  J Biol Chem       Date:  2013-04-11       Impact factor: 5.157

6.  A phase 3 trial of IV immunoglobulin for Alzheimer disease.

Authors:  Norman R Relkin; Ronald G Thomas; Robert A Rissman; James B Brewer; Michael S Rafii; Christopher H van Dyck; Clifford R Jack; Mary Sano; David S Knopman; Rema Raman; Paul Szabo; David M Gelmont; Sandor Fritsch; Paul S Aisen
Journal:  Neurology       Date:  2017-04-05       Impact factor: 9.910

7.  ELISA measurement of specific non-antigen-bound antibodies to Aβ1-42 monomer and soluble oligomers in sera from Alzheimer's disease, mild cognitively impaired, and noncognitively impaired subjects.

Authors:  Andrea C Klaver; Mary P Coffey; Lynnae M Smith; David A Bennett; John M Finke; Loan Dang; David A Loeffler
Journal:  J Neuroinflammation       Date:  2011-08-09       Impact factor: 8.322

8.  Detection of Soluble Amyloid-β Oligomers and Insoluble High-Molecular-Weight Particles in CSF: Development of Methods with Potential for Diagnosis and Therapy Monitoring of Alzheimer's Disease.

Authors:  Susanne Aileen Funke
Journal:  Int J Alzheimers Dis       Date:  2011-11-02

9.  Alzheimers disease: review of emerging treatment role for intravenous immunoglobulins.

Authors:  Rakez Kayed; George R Jackson; D Mark Estes; Alan D T Barrett
Journal:  J Cent Nerv Syst Dis       Date:  2011-05-08

10.  Human anti-Aβ IgGs target conformational epitopes on synthetic dimer assemblies and the AD brain-derived peptide.

Authors:  Alfred T Welzel; Angela D Williams; Helen P McWilliams-Koeppen; Luis Acero; Alfred Weber; Veronika Blinder; Alex Mably; Sebastian Bunk; Corinna Hermann; Michael A Farrell; Hartmut J Ehrlich; Hans P Schwarz; Dominic M Walsh; Alan Solomon; Brian O'Nuallain
Journal:  PLoS One       Date:  2012-11-27       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.